Keratoconjunctivitis sicca (Dry Eye) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Keratoconjunctivitis sicca (KCS) or dry eye disease (DED) or dry eye syndrome (DES) symptoms include hyperemia, mucoid discharge, ocular irritation, photophobia, and blurry vision. Risk factors include age, wearing contact lenses and low levels of vitamin A. Treatment includes artificial tear substitutes, topical anti-inflammatory agents, secretagogues, and immunosuppressants.
The KCS pipeline drugs market research report provides an analysis of the KCS drugs by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The guide also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for KCS and features dormant and discontinued projects.
Key Targets of the KCS Pipeline Drugs Market
Some of the targets of the KCS pipeline drugs market are Calcineurin, Glucocorticoid Receptor, Actin, Cannabinoid Receptor 1, Cannabinoid Receptor 2, Cystic Fibrosis Transmembrane Conductance Regulator, Integrin Alpha L, Adiponectin Receptor Protein 1, and High Affinity Nerve Growth Factor Receptor among others.
KCS Pipeline Drugs Market, by Key Targets
For more insights on key targets, download a free report sample
Key Mechanisms of Action in the KCS Pipeline Drugs Market
The key mechanisms of action of the KCS pipeline drugs market are Calcineurin Inhibitor, Glucocorticoid Receptor Agonist, Actin Inhibitor, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, Cystic Fibrosis Transmembrane Conductance Regulator Activator, Adiponectin Receptor Protein 1 Agonist, High Affinity Nerve Growth Factor Receptor Agonist, and Integrin Alpha L Antagonist among others.
KCS Pipeline Drugs Market, by Key Mechanisms of Action
For more insights on key mechanisms of action, download a free report sample
Key Routes of Administration in the KCS Pipeline Drugs Market
The routes of administration in the KCS pipeline drugs market are ophthalmic, topical, oral, intravenous, transdermal, intraocular, nasal, and parenteral among others.
KCS Pipeline Drugs Market, by Routes of Administration
For more insights on routes of administration, download a free report sample
Key Molecule Types in the KCS Pipeline Drugs Market
The molecule types in the KCS pipeline drugs market are Small Molecule, Synthetic Peptide, Recombinant Protein, Biologic, Peptide, Synthetic Protein, and Antibody among others.
KCS Pipeline Drugs Market, by Molecule Types
For more insights on molecule type, download a free report sample
Key Companies in the KCS Pipeline Drugs Market
Some of the key companies in the KCS pipeline drugs market are Azura Ophthalmics Pty Ltd, Aldeyra Therapeutics Inc, AxeroVision Inc, Intratus Inc, Novaliq GmbH, Ocular Therapeutix Inc, RegeneRx Biopharmaceuticals Inc, and AbbVie Inc among others.
KCS Pipeline Drugs Market, by Companies
For more insights on companies, download a free report sample
KCS Pipeline Drugs Market Report Overview
Key Targets | Calcineurin, Glucocorticoid Receptor, Actin, Cannabinoid Receptor 1, Cannabinoid Receptor 2, Cystic Fibrosis Transmembrane Conductance Regulator, Integrin Alpha L, Adiponectin Receptor Protein 1, and High Affinity Nerve Growth Factor Receptor |
Key Mechanisms of Action | Calcineurin Inhibitor, Glucocorticoid Receptor Agonist, Actin Inhibitor, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, Cystic Fibrosis Transmembrane Conductance Regulator Activator, Adiponectin Receptor Protein 1 Agonist, High Affinity Nerve Growth Factor Receptor Agonist, and Integrin Alpha L Antagonist |
Key Routes of Administration | Ophthalmic, Topical, Oral, Intravenous, Transdermal, Intraocular, Nasal, and Parenteral |
Key Molecule Types | Small Molecule, Synthetic Peptide, Recombinant Protein, Biologic, Peptide, Synthetic Protein, and Antibody |
Key Companies | Azura Ophthalmics Pty Ltd, Aldeyra Therapeutics Inc, AxeroVision Inc, Intratus Inc, Novaliq GmbH, Ocular Therapeutix Inc, RegeneRx Biopharmaceuticals Inc, and AbbVie Inc |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
AbbVie Inc
Abilita Bio Inc
Actinobac Biomed Inc
Aerie Pharmaceuticals Inc
Aldeyra Therapeutics Inc
Allegro Ophthalmics LLC
Allgenesis Biotherapeutics Inc
Allosterix Ltd
Allysta Pharmaceuticals Inc
APIRx Pharmaceuticals USA LLC
Aramis Biosciences Inc
Ascendia Pharmaceuticals Inc
Aviara Pharmaceuticals Inc
Avixgen Inc
AxeroVision Inc
Azura Ophthalmics Pty Ltd
Bessor Pharma LLC
BRIM Biotechnology Inc
BSIM Therapeutics SA
Cambium Medical Technologies LLC
Cellix Bio Pvt Ltd
Chengdu Kanghong Pharmaceuticals Group Co Ltd
Chong Kun Dang Pharmaceutical Corp
Cloudbreak Therapeutics LLC
Curexsys GmbH
Curigin Co Ltd
Daewoo Pharmaceutical Co Ltd
Daewoong Pharmaceutical Co Ltd
DHP Korea Co Ltd
Dompe Farmaceutici SpA
EncuraGen Co Ltd
Eye Bio Korea Co Ltd
FirstString Research Inc
GL Pharm Tech Corp
Glaukos Corp
Glia LLC
H4Orphan Pharma
HanAll Biopharma Co Ltd
Huons Co Ltd
Huons Global Co Ltd
IACTA Pharmaceuticals Inc
Icure Pharmaceutical Inc
Ildong Pharmaceutical Co Ltd
Intratus Inc
Invitrx Therapeutics Inc
Ipsen SA
IVIEW Therapeutics Inc
Japan Tobacco Inc
Juvenescence UK Ltd
Kala Pharmaceuticals Inc
Kiora Pharmaceuticals Inc
Kowa Co Ltd
Kukje Pharmaceutical Industry Co Ltd
Laboratoires Thea SA
Link Biologics Ltd
LTT Bio-Pharma Co Ltd
Marinomed Biotech AG
MC2 Therapeutics AS
Medicon Pharmaceuticals Inc
MediPrint Ophthalmics Inc
MeiraGTx Holdings Plc
Merck & Co Inc
Mimetogen Pharmaceuticals Inc
Mitotech SA
MyX Therapeutics Inc
Nanomerics Ltd
Neuroptika Inc
NicOx SA
Ningbo Xijian Pharmaceutical Technology Co Ltd
NovaCell Technology Inc
Novaliq GmbH
Novartis AG
Noveome Biotherapeutics Inc
OccuRx Pty Ltd
Ocular Therapeutix Inc
Oculis SA
Ocumension Therapeutics
OKYO Pharma Ltd
OncoNOx ApS
Ophrx Ltd
Oyster Point Pharma Inc
Palatin Technologies Inc
Panag Pharma Inc
PharmaResearch Co Ltd
Pinotbio Inc
Pleryon Therapeutics Ltd
Proteris Biotech Inc
Protokinetix Inc
Qilu Pharmaceutical Co Ltd
Quorum Innovations LLC
Redwood Pharma AB
RegeneRx Biopharmaceuticals Inc
Reven Holdings Inc
Rhizen Pharmaceuticals SA
RHNanopharmacuticals LLC
RiniSight Inc
Rudacure Co Ltd
Samjin Pharm Co Ltd
Santen Pharmaceutical Co Ltd
SCAI Therapeutics
Seinda Pharmaceutical Guangzhou Corp
Senju Pharmaceutical Co Ltd
Serentrix LLC
Shenzhen Evergreen Therapeutics Co Ltd
SIFI SpA
Silk Technologies Ltd
Sinobioway Biomedical Co Ltd
Skye Bioscience Inc
Sol-Gel Technologies Ltd
Stuart Therapeutics Inc
Sun Pharmaceutical Industries Ltd
Surface Pharmaceuticals Inc
Surrozen Inc
Sylentis SAU
TaeJoon Pharmaceuticals Co Ltd
TagCyx Biotechnologies
Tarsius Pharma Ltd
TearSolutions Inc
Tetra Bio-Pharma Inc
Vanda Pharmaceuticals Inc
Viva Vision Biotech
Yuyu Pharma Inc
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd
Zhuhai Qiwei Biotechnology Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the targets of the KCS pipeline drugs market?
Some of the targets of the KCS pipeline drugs market are Calcineurin, Glucocorticoid Receptor, Actin, Cannabinoid Receptor 1, Cannabinoid Receptor 2, Cystic Fibrosis Transmembrane Conductance Regulator, Integrin Alpha L, Adiponectin Receptor Protein 1, and High Affinity Nerve Growth Factor Receptor.
-
What are the mechanisms of action of the KCS pipeline drugs market?
The key mechanism of action of the KCS pipeline drugs market are Calcineurin Inhibitor, Glucocorticoid Receptor Agonist, Actin Inhibitor, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, Cystic Fibrosis Transmembrane Conductance Regulator Activator, Adiponectin Receptor Protein 1 Agonist, High Affinity Nerve Growth Factor Receptor Agonist, and Integrin Alpha L Antagonist.
-
What are the routes of administration in the KCS pipeline drugs market?
The routes of administration in the KCS pipeline drugs market are ophthalmic, topical, oral, intravenous, transdermal, intraocular, nasal, and parenteral.
-
What are the molecule types in the KCS pipeline drugs market?
The molecule types in the KCS pipeline drugs market are Small Molecule, Synthetic Peptide, Recombinant Protein, Biologic, Peptide, Synthetic Protein, and Antibody.
-
Which are the key companies in the KCS pipeline drugs market?
Some of the key companies in the KCS pipeline drugs market are Azura Ophthalmics Pty Ltd, Aldeyra Therapeutics Inc, AxeroVision Inc, Intratus Inc, Novaliq GmbH, Ocular Therapeutix Inc, RegeneRx Biopharmaceuticals Inc, and AbbVie Inc among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.